Adquey is a drug owned by Acrotech Biopharma Inc. It is protected by 2 US drug patents filed in 2026 out of which none have expired yet. Adquey's patents will be open to challenges from 12 February, 2030. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 31, 2036. Details of Adquey's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US10588893 | Ointment Containing An Oxazole Compound |
Dec, 2036
(10 years from now) | Active |
| USRE46792 | NA |
Mar, 2028
(1 year, 10 months from now) | Active |
FDA has granted several exclusivities to Adquey. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Adquey, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Adquey.
Exclusivity Information
Adquey holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2031. Details of Adquey's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 12, 2031 |
US patents provide insights into the exclusivity only within the United States, but
Adquey is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Adquey's family patents as well as insights into
ongoing legal events
on those patents.
Adquey's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Adquey's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 31, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Adquey Generics:
There are no approved generic versions for Adquey as of now.
About Adquey
Adquey is a drug owned by Acrotech Biopharma Inc. Adquey uses Difamilast as an active ingredient. Adquey was launched by Acrotech in 2026.
Approval Date:
Adquey was approved by FDA for market use on 12 February, 2026.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Adquey is 12 February, 2026, its NCE-1 date is estimated to be 12 February, 2030.
Active Ingredient:
Adquey uses Difamilast as the active ingredient. Check out other Drugs and Companies using Difamilast ingredient
Dosage:
Adquey is available in ointment form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1% | OINTMENT | Prescription | TOPICAL |